A WORD FROM OUR CHIEF SCIENTIFIC OFFICER
Dear FAPI Community,
I hope everyone has enjoyed their summer and found some time for rest and relaxation.
We are inspired to see the conversation about FAPI’s applications continue to evolve, as reflected by its presence in programs for two scientific meetings this fall. I, and other members of the SOFIE team, will be attending the annual EANM Congress, on October 19-23 in Hamburg, Germany. We hope to see many of you there.
SOFIE is proud to be a Silver Sponsor of the ICPO Theranostics Virtual Summit on November 14-15. As part of the FAP session on Day 2, I will be providing an update on our SOFIE-sponsored clinical trials. More information on the Summit program and registration is included below.
Here in the US, our Romeoville, IL, site is cleared for production of [18F]-FAPI-74. We now have three sites (in addition to Gilroy, CA, and Totowa, NJ) for manufacturing of GMP grade [18F]-FAPI-74 for clinical research for academics and pharma services, with more sites planned in the coming year.
We want to acknowledge and thank those of you participating in our Global Outreach Program. In accordance with the terms of your MTA with iTheranostics/SOFIE, we will be sending out an annual progress report. Please be on the lookout and complete the short questionnaire. We appreciate this partnership and wish you all the best with your research progress utilizing FAPI.
As always, it’s a pleasure to connect with our FAPI community. Any suggestions you have on how this newsletter can become a better resource for you are welcome.
UPCOMING ICPO THERANOSTICS VIRTUAL SUMMIT
The 2024 ICPO Theranostics Virtual Summit, “Radiotheranostics: New Era for Alpha Emitters and Radiopharmaceuticals”, is scheduled November 14-15, 2024. Featured in the robust scientific program are sessions on FAP diagnostics and therapy, and a panel on FAP as an imaging biomarker. SOFIE proudly supports this event with leading academy and industry experts, and further champion the ICPO’s efforts on improving patient outcomes. Click here to register for this summit.
99mTc-HFAPi SPECT imaging predicts left ventricular remodeling after acute myocardial infarction
J Nucl Cardiol. 2024 Jul 14
FAPI OUTREACH PROGRAM
Join us in advancing the frontier of molecular imaging through the FAPI Outreach Program
SOFIE is continuing to accept applications for our FAPI Outreach Program. This program aims to raise awareness and foster collaboration in the field of molecular imaging, specifically focusing on Fibroblast Activation Protein Inhibitor (FAPI) studies. This program seeks to engage with healthcare professionals, researchers, and the broader community to share knowledge, advancements, and the potential impact of FAPI in diagnostic and therapeutic applications.
*GE Healthcare licensed products and regions will be ready for new application reviews in April.